Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM8X2EH)

Drug Name
Everolimus Drug Info
Synonyms
Afinitor; Afinitor (TN); CERTICAN(R); Certican; Certican (TN); Everolimus (JAN/USAN/INN); Everolimus [USAN]; MTOR kinase inhibitors; NVP-RAD-001; RAD 001; RAD-001; RAD-001C; RAD001; RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus; SDZ-RAD; Zortress
Therapeutic ClassAnticancer Agents
Cross-matching ID
PubChem CID
6442177
ChEBI ID
CHEMBL68478
CAS Number
CAS 159351-69-6
TTD Drug ID
D0K3QS
VARIDT Drug ID
DR00224
INTEDE Drug ID
DR0674
ACDINA Drug ID
D00260

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Focal adhesion 2.18 0.00e+0 180/201 (89.55%) FN1;PDGFC;PDGFD;...
Transcriptional misregulation in cancer 2.05 0.00e+0 158/192 (82.29%) DUSP6;MYC;PROM1;...
MicroRNAs in cancer 2.02 0.00e+0 146/310 (47.1%) MYC;IRS2;MARCKS;...
ECM-receptor interaction 2.01 0.00e+0 80/88 (90.91%) FN1;CD44;THBS1;...
Small cell lung cancer 2.01 0.00e+0 90/92 (97.83%) MYC;FN1;CDKN1B;...
AGE-RAGE signaling pathway in diabetic complications 1.98 0.00e+0 97/100 (97%) FN1;CDKN1B;TGFB1;...
Proteoglycans in cancer 1.95 0.00e+0 172/205 (83.9%) MYC;FN1;CD44;...
Notch signaling pathway 1.93 0.00e+0 49/59 (83.05%) TLE4;ATXN1;JAG1;...
Gastric cancer 1.84 7.94e-3 122/149 (81.88%) MYC;JUP;CDKN1B;...
Basal cell carcinoma 1.83 7.14e-3 41/63 (65.08%) TP53;TCF7L1;PTCH1;...
NF-kappa B signaling pathway 1.81 7.58e-3 90/104 (86.54%) NFKBIA;RELB;PLCG2;...
Prostate cancer 1.81 7.94e-3 93/97 (95.88%) PDGFC;PDGFD;CDKN1B;...
Human papillomavirus infection 1.81 8.24e-3 284/331 (85.8%) FN1;THBS1;CDKN1B;...
TGF-beta signaling pathway 1.80 7.65e-3 81/94 (86.17%) MYC;ID1;INHBA;...
PI3K-Akt signaling pathway 1.75 1.98e-2 317/354 (89.55%) MYC;FN1;EFNA1;...
Regulation of actin cytoskeleton 1.75 1.86e-2 185/218 (84.86%) FN1;PDGFC;F2R;...
Bladder cancer 1.75 1.75e-2 40/41 (97.56%) MYC;THBS1;TP53;...
Rap1 signaling pathway 1.74 1.79e-2 184/210 (87.62%) EFNA1;PDGFC;ID1;...
Hippo signaling pathway 1.74 1.69e-2 120/186 (64.52%) MYC;CCN2;ID1;...
Hepatocellular carcinoma 1.73 1.85e-2 135/168 (80.36%) MYC;TP53;FRAT1;...
Breast cancer 1.72 1.81e-2 119/147 (80.95%) MYC;TP53;FRAT1;...
Leukocyte transendothelial migration 1.71 1.89e-2 90/114 (78.95%) PLCG2;ACTN1;MMP9;...
Amoebiasis 1.70 1.97e-2 99/102 (97.06%) FN1;GNAS;TGFB1;...
Endometrial cancer 1.69 2.18e-2 56/58 (96.55%) MYC;TP53;TCF7L1;...
Osteoclast differentiation 1.68 2.24e-2 117/127 (92.13%) NFKBIA;TGFB1;RELB;...
Wnt signaling pathway 1.67 2.16e-2 124/166 (74.7%) MYC;TLE4;SFRP1;...
Leishmaniasis 1.67 2.13e-2 67/77 (87.01%) MARCKSL1;NFKBIA;TGFB1;...
Shigellosis 1.67 2.09e-2 180/246 (73.17%) CD44;TP53;NFKBIA;...
Pancreatic cancer 1.67 2.22e-2 75/76 (98.68%) TP53;TGFB1;AKT3;...
Pathways in cancer 1.66 2.30e-2 474/531 (89.27%) MYC;FN1;F2R;...
Fatty acid biosynthesis -1.56 4.73e-2 16/18 (88.89%) ACSL4;ACSL6;ACSL5;...
Thiamine metabolism -1.57 4.44e-2 12/15 (80%) ALPI;AK1;ACP1;...
Parkinson disease -1.57 4.62e-2 176/249 (70.68%) PSMC5;ADRM1;PSMB7;...
Synthesis and degradation of ketone bodies -1.58 4.33e-2 9/10 (90%) OXCT1;HMGCS2;BDH1;...
Steroid hormone biosynthesis -1.59 3.91e-2 43/61 (70.49%) CYP2E1;CYP19A1;HSD17B6;...
Glyoxylate and dicarboxylate metabolism -1.61 3.29e-2 23/30 (76.67%) SHMT1;ACO1;GLUL;...
Arginine and proline metabolism -1.61 3.42e-2 39/50 (78%) GOT2;SRM;ODC1;...
Propanoate metabolism -1.69 1.65e-2 30/34 (88.24%) ACSS3;DBT;PCCA;...
Aminoacyl-tRNA biosynthesis -1.70 1.34e-2 15/66 (22.73%) QRSL1;CARS2;LARS2;...
Ferroptosis -1.73 1.09e-2 36/41 (87.8%) ACSL6;SLC11A2;LPCAT3;...
RNA transport -1.75 8.54e-3 128/186 (68.82%) POP5;NUP54;NUP43;...
Fatty acid elongation -1.76 8.57e-3 19/27 (70.37%) HADHA;PPT2;ELOVL2;...
Pyruvate metabolism -1.77 7.46e-3 41/47 (87.23%) ADH5;ME2;FH;...
Protein processing in endoplasmic reticulum -1.82 2.47e-3 127/171 (74.27%) SSR3;DNAJC10;DNAJC3;...
Folate biosynthesis -1.92 6.70e-4 23/26 (88.46%) AKR1B1;ALPI;GPHN;...
Glycine, serine and threonine metabolism -1.97 7.31e-4 31/40 (77.5%) GLDC;PGAM1;DLD;...
Steroid biosynthesis -2.01 8.04e-4 19/20 (95%) SC5D;LSS;NSDHL;...
Terpenoid backbone biosynthesis -2.01 8.93e-4 18/22 (81.82%) PCYOX1;GGPS1;FDPS;...
PPAR signaling pathway -2.15 0.00e+0 66/74 (89.19%) FABP3;ACOX2;SLC27A6;...
Cysteine and methionine metabolism -2.15 0.00e+0 43/50 (86%) APIP;GCLC;KYAT3;...
Alanine, aspartate and glutamate metabolism -2.18 0.00e+0 27/37 (72.97%) GFPT2;NIT2;ASRGL1;...
Biosynthesis of unsaturated fatty acids -2.21 0.00e+0 21/27 (77.78%) ACOX1;SCP2;HACD1;...
Arginine biosynthesis -2.21 0.00e+0 17/22 (77.27%) GLUL;GOT2;ARG2;...
Citrate cycle (TCA cycle) -2.21 0.00e+0 30/30 (100%) ACLY;FH;PDHA1;...
Ribosome biogenesis in eukaryotes -2.26 0.00e+0 52/108 (48.15%) TCOF1;RPP30;RAN;...
Proteasome -2.29 0.00e+0 44/46 (95.65%) IFNG;PSMC5;ADRM1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Bone marrow
Chronic myeloid leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
K-562 CVCL_0004 Homo sapiens 0.01uM - 10uM 4H, 24H
Multiple myeloma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
KMS-34 CVCL_1333 Homo sapiens 0.01uM - 10uM 24H
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUES 3 CVCL_B062 Homo sapiens 0.04uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Lymph node
Burkitt lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BJAB CVCL_5711 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Diffuse large B-cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HBL-1 CVCL_4213 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly10 CVCL_8795 Homo sapiens 0.01uM - 10uM 24H
OCI-Ly19 CVCL_8797 Homo sapiens 0.01uM - 10uM 4H, 24H
OCI-Ly3 CVCL_8796 Homo sapiens 0.01uM - 10uM 4H, 24H
TMD8 CVCL_A440 Homo sapiens 0.01uM - 10uM 3H, 4H, 6H, 24H
Mantle cell lymphoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MINO CVCL_4965 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 6H, 24H
Peripheral blood
Acute B-lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NALM-6 CVCL_0092 Homo sapiens 0.01uM - 10uM 24H
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 3H, 6H, 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H
SK-MEL-5 CVCL_0527 Homo sapiens 0.01uM - 10uM 24H